Evolution of tumefactive lesions in multiple sclerosis: a 12-year study with serial imaging in a single patient

Mult Scler. 2013 Oct;19(11):1539-43. doi: 10.1177/1352458513498124.

Abstract

We describe the acute presentation and the long-term evolution of recurrent tumefactive lesions (TLs) in a patient with relapsing-remitting multiple sclerosis. Five TLs occurred on three different occasions over a period of 12 years and these were followed by 73 serial magnetic resonance images (MRI). TL evolution was described by means of magnetization transfer imaging (MTI) and cerebrospinal fluid tissue specific imaging (TSI) over the follow-up period. During the study period, the patient had three clinical relapses with only minimal disability progression. MTI demonstrated that only the peripheral portion of each TL reverted to pre-lesional MT ratios within six months' post-enhancement. Recurring TLs may present a similar pattern of evolution that may be associated with a long-term favourable clinical outcome.

Keywords: Multiple sclerosis; magnetic resonance imaging; magnetization transfer imaging; recovery; tissue-specific imaging; tumefactive lesion.

Publication types

  • Case Reports
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Brain / pathology*
  • Daclizumab
  • Disease Progression
  • Glatiramer Acetate
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunologic Factors / therapeutic use
  • Interferon beta-1a
  • Interferon-beta / therapeutic use
  • Longitudinal Studies
  • Magnetic Resonance Imaging
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting / pathology*
  • Myelin Basic Protein / therapeutic use
  • Peptide Fragments / therapeutic use
  • Peptides / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • CGP 77116
  • Immunoglobulin G
  • Immunologic Factors
  • Myelin Basic Protein
  • Peptide Fragments
  • Peptides
  • Glatiramer Acetate
  • Interferon-beta
  • Daclizumab
  • Interferon beta-1a